Clinical trial NCT02185677: Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy
Official title: Comparison of Cognitive and Behavioral Dysexecutive Syndrome Between Parkinsonian Form and Cerebellar Form of Multiple System Atrophy and Analysis of Correlates With an Imaging Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple System Atrophy
Keywords: dysexecutive syndrome
multiple system atrophy
imaging study
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2014-07-09
Enrollment: 40
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients suffering from MSA-P or MSA-C

Brief summary: The main objective of the study is to compare the score to the Behavioral Dysexecutive Syndrome Inventory (BDSI) between Parkinsonian Multiple system Atrophy MSA-P patients and cerebellar Multiple System Atrophy (MSA-C) patients matched on disease duration, age (± 7 years) and sex .

Detailed description: Multiple system atrophy (MSA) is a rare neurodegenerative disorder which is characterized by a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and additional signs. According to the consensus criteria for the diagnosis of MSA, the presence of dementia is considered an exclusion criteria. However, several studies have reported cognitive impairment in patients with MSA, dominated by a dysexecutive syndrome. Some studies have compared the cognitive profile of MSA-P patients and MSA-C but any have studied the behavioral dysexecutive syndrome in this population. In 2010, the GREFFEX has established criteria for dysexecutive syndrome and described two distinct parts: the dysexecutive syndrome and cognitive behavioral dysexecutive syndrome. Our clinical impression is that according to the type of MSA, the dysexecutive syndrome seems to be different : the MSA-P patients seem to have a cognitive dysexecutive syndrome and the MSA-C patients a behavioral dysexecutive syndrome.

We want to compare the BDSI score between MSA-P patients and MSA-C patients matched on disease duration, age and sex The specific involvement of the cerebellum in behavioral disorders could explain the behavioral differences experienced by clinicians caring for these patients but never demonstrated. The presence of these disorders could have an impact on the relationship between the patient and the caregiver. In addition, few studies have correlated with cognitive imagery data. Therefore, the exact areas involved in cognitive and behavioral MSApatients remain poorly understood.

Eligibility criteria: Inclusion criteria:

* Patients suffering from "probable" MSA according to clinical consensus criteria (Gilman et al, 2008),
* Age \>30
* Written informed consent
* Patient covered by the national health system
* The presence of an informant
* Blood negative dosage of the hormone béta-hCG for the women old enough to procreate

Exclusion criteria:

* UMSARS IV score \> 4 points
* Pregnant woman (blood positive dosage of the hormone béta-hCG) or breast feeding
* Patient under tutelage
* Patient unable to give consent
* Against indication to perform an MRI

Primary outcomes:
measure: Behavioral Dysexecutive Syndrome Inventory scores
timeFrame: At inclusion (day 0)
Secondary outcomes:
measure: To compare the subscores of the BDSI between MSA-P patients and MSA-C patients.
timeFrame: At inclusion (Day 0)
measure: To compare the cognitive tests exploring the cognitive dysexecutive syndrome between MSA-P patients and MSA-C patients.
timeFrame: At inclusion (Day 0)
measure: To research correlations between scores UMSARS and cognitive and behavioral scores for MSA-P patients and MSA-C patients.
timeFrame: At inclusion (Day 0)
measure: To compare atrophied brain areas, the anatomic and functional abnormalities of neural networks between MSA-P patients and MSA-C patients.
timeFrame: At inclusion (Day 0)
measure: To research correlations between imaging abnormalities and cognitive test performance in MSA patients.
timeFrame: At inclusion (day 0)
measure: Actigraphy
timeFrame: During 7 days after inclusion
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: CHU de Bordeaux
Study officials:
affiliation: University Hospital, Bordeaux
name: Alexandra FOUBERT-SAMIER, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital, Bordeaux
name: Rodolphe THIEBAUT, MD, PhD
role: STUDY_CHAIR
References: